Peroxisome proliferator-activated receptors and alzheimer's disease: Hitting the blood-brain barrier

Molecular Neurobiology

Volumn 48, Issue 3, 2013, Pages 438-451

  Zolezzi, Juan M ^a   Inestrosa, Nibaldo C ^a,b  

^a Centro de Envejecimiento y Regeneración CARE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Alzheimer's disease; Blood brain barrier; Oxidative stress; PPARs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA CATENIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; ARMADILLO DOMAIN PROTEIN; BETA CATENIN; BEXAROTENE; BREAST CANCER RESISTANCE PROTEIN; CD31 ANTIGEN; CELL NUCLEUS RECEPTOR; CLAUDIN; CLUSTERIN; ENDOTHELIAL PROTEIN C RECEPTOR; GLUCOSE TRANSPORTER 1; INSULIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MONOCARBOXYLATE TRANSPORTER 1; MULTIDRUG RESISTANCE PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLAKOGLOBIN; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TAU PROTEIN; TROGLITAZONE; VASCULAR ENDOTHELIAL CADHERIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ASTROCYTE; BLOOD BRAIN BARRIER; CELL ADHESION; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; COGNITIVE DEFECT; ENDOTHELIUM CELL; GLIA CELL; HIPPOCAMPUS; HUMAN; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS; VASCULAR AMYLOIDOSIS; WNT SIGNALING PATHWAY;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; MODELS, BIOLOGICAL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84888009677     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8435-5     Document Type: Review

References (134)

1. Lewandowsky M (1900) ZurLehre der Cerebrospinal flussigkeit. Z Klin Med 40:480-494
2. Biedl A, Kraus R (1898) ÜbereinerbisherunbekanntetoxischeWikung der Gallensauren auf das Zentral-nervensystem. ZentralblattInnereMedizin 19:1185-1200
3. Goldmann EE (1909) Die aussere und innereSekretion des gesunden und krankenOrganismusimLichte der 'vitalenFarbung'. BeitraegeKlinischenChirurgie 64:192-265
4. Goldmann EE (1913) Vitalfarbung am Zentral-nervensystem. AbhandlungenPreussischenAkademie der WissenschaftenPhysikalischMathematischklasse I 1-60
5. Krogh A (1946) The active and passive exchanges of inorganic ions through the surfaces of living cells and through living membranes generally. Proc Biol Sci 133:140-200
6. Schultz RL, Maynard EA, Pease DC (1957) Electron microscopy of neurons and neuroglia of cerebral cortex and corpus callosum. Am J Anat 100:369-407
7. Reese TS, Karnovsky MJ (1967) Structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207-217
8. Brightman MW, Reese TS (1969) Junctions between intimately opposed cell membranes in the vertebrate brain. J Cell Biol 40:648-677
9. Abbott NJ (2004) Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 1:407-416
10. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37:13-25
11. Liebner S, Plate KH (2010) Differentiation of the brain vasculature: the answer came blowing by the Wnt. J Angiogenes Res 2:1
12. Girouard H, Iadecola C (2006) Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 100:328-335
13. Schulze C, Firth JA (1993) Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. J Cell Sci 104:773-782
14. Roberts J, Kahle MP, Bix GJ (2012) Perlecan and the blood-brain barrier: beneficial proteolysis. Front Pharmacol 3:155
15. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12:54-61
16. Wilhelm I, Fazakas C, Krizbai IA (2011) In vitro models of the blood-brain barrier. Acta NeurobiolExp 71:113-128
17. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201
18. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S (1993) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123:1777-1788
19. Gonzáles-Mariscal L, Betanzos A, Nava P, Jaramillo BE (2003) Tight junction proteins. Prog Biophys Mol Biol 81:1-44
20. Nasdala I, Wolburg-Buchholz K, Wolburg H, Kuhn A, Ebnet K, Brachtendorf G, Samulowitz U, Kuster B, Engelhardt B, Vestweber D, Butz S (2002) A transmembrane tight junction protein selectively expressed on endotelial cells and platelets. J Biol Chem 277:16294-16303
21. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E (1998) Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercelular junctions and modulates monocyte transmigration. J Cell Biol 142:117-127
22. Bazzoni G, Tonetti P, Manzi L, Cera MR, Balconi G, Dejana E (2005) Expression of junctional adhesion molecule-A prevents spontaneous and random motility. J Cell Sci 118:623-632
23. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA (1986) Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 103:755-766
24. Gumbiner B, Lowenkopf T, Apatira D (1991) Identification of a 160-kDa polypeptide that binds to the tight junction protein ZO-1. Proc Natl Acad Sci USA 88:3460-3464
25. Hawkins BT, Davis TP (2005) The blood-brain barrier neurovascular unit in health and disease. Pharmacol Rev 57:173-185
26. Ohnishi H, Nakahara T, Furuse K, Sasaki H, Tsukita S, Furuse M (2004) JACOP, a novel plaque protein localizing at the apical junctional complex with sequence similarity to cingulin. J Biol Chem 279:46014-46022
27. Breier G, Breviario F, Caveda L, Berthier R, Schnürch H, Gotsch U, Vestweber D, Risau W, Dejana E (1996) Molecular cloning and expression of murine vascular endotelial-cadherin in early stage development of cardiovascular system. Blood 87:630-641
28. Redzic Z (2011) Molecular biology of the blood-brain and the blood-cerebrospinal fluid barrier: similarities and differences. Fluid Barriers CNS 8:3
29. O'Kane RL, Martinez-Lopez I, DeJoseph MR, Vina JR, Hawkins RA (1999) Na + -dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-barrier. A mechanism for glutamate removal. J Biol Chem 274:31891-31895
30. Zlokovic BV (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12:723-738
31. Do TM, Noel-Hudson MS, Ribes S, Besengez C, Smirnova M, Cisternino S, Buyse M, Calon F, Chimini G, Chacun H, Scherrmann JM, Farinotti R, Bourasset F (2012) ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. J Alzheimers Dis 30:155-166
32. Pardridge WM (2005) Molecular biology of the blood-brain barrier. Mol Biotechnol 30:57-70
33. Banks WA (2006) The CNS as a target for peptides and peptide-based drugs. Expert Opin Drug Deliv 3:707-712
34. O'Donnell ME, Lam TI, Tran LQ (2006) Estradiol reduces activity of the blood-brain barrier Na-K-Cl cotransporter and decreases edema formation in permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab 26:1234-1249
35. Taylor CJ, Nicola PA, Wang S, Barrand MA, Hladky SB (2006) Transporters involved in regulation of intracellular pH in primary cultured rat brain endothelial cells. J Physiol 576:769-785
36. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V (2007) Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 6:258-268
37. Parton RG, Richards AA (2003) Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 4:724-738
38. Roux F, Durieu-Trautmann O, Chaverot N, Claire M, Mailly P, Bourre JM, Strosberg AD, Couraud PO (1994) Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol 159:101-113
39. Régina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, Roux F (1998) Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71:705-715
40. Deli MA, Abrahám CS, Takahata H, Niwa M (2001) Tissue plasminogen activator inhibits P-glycoprotein activity in brain endothelial cells. Eur J Pharmacol 411:R3-R5.46
41. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377:1019-1031
42. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M (2003) Evaluation of the immortalized mouse brain capillary endothelial cell line, b.End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 990:95-112
43. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Levenque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO (2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872-1874
44. Sagare AP, Bell RD, Zlokovic BV (2012) Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med. doi: 10.1101/cshperspect.a011452
45. Heinemann U, Kaufer D, Friedman A (2012) Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia 60:1251-1257
46. Marchi N, Granata T, Ghosh C, Janigro D (2012) Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches. Epilepsia. doi: 10.1111/j.1528-1167.2012.03637.x
47. Morgan L, Shah B, Rivers LE, Barden L, Groom AJ, Chung R, Higazi D, Desmond H, Smith T, Staddon JM (2007) Inflammation and dephosphorylation of the tight junction protein occluding in an experimental model of multiple sclerosis. Neuroscience 147:664-673
48. Salmon DP, Bondi MW (2009) Neuropsychological assessment of dementia. Annu Rev Psychol 60:257-282
49. Perl DP (2010) Neuropathology of Alzheimer's disease. Mt Sinai J Med 77:32-42
50. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, Chen G (2012) Impaired mitochondrial function in psychiatric disorders. Nature Rev Neurosci 13:293-307
51. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3:75-80
52. Bailey TL, Rivara CB, Rocher AB, Hof PR (2004) The nature and effects of cortical microvascular pathology in aging and Alzheimer's disease. Neurol Res 26:573-578
53. Cramer PE, Cirrito JR, Wesson DW, Daniel Lee CY, Colleen KJ, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335:1503-1506
54. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118:103-113
55. Kanekiyo T, Liu C, Shinohara M, Li J, Bu G (2012) LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J Neurosci 32:16458-16465
56. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoprotein E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909-918
57. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-β protein, and impairs cognition. J Biol Chem 258:22091-22102
58. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M (2011) Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 286:17536-17542
59. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V (2012) Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiol Aging 33:628, e1-628.e14
60. Qosa H, Abuznait AH, Hill RA, Kaddoumi A (2012) Enhanced brain amyloid-β clearance by rifampicin and caffeine as possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 31:151-165
61. Nielsen HM, Mulder SD, Beliën JA, Musters RJ, Eikelenboom P, Veerhuis R (2010) Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 58:1235-1246
62. Kamboh MI, Minster RL, Demirci FY, Ganguli M, Dekosky ST, Lopez OL, Barmada MM (2012) Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging 33:518-521
63. Erickson MA, Niehoff ML, Farr SA, Morley JE, Dillman LA, Banks WA (2012) Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain. J Alzheimers Dis 28:951-960
64. Natunen T, Helisalmi S, Vepsäläinen S, Sarajärvi T, Antikainen L, Mäkinen P, Herukka SK, Koivisto AM, Haapasalo A, Soininen H, Hiltunen M (2012) Genetic analysis of genes involved in amyloid-β degradation and clearance in Alzheimer's disease. J AlzheimersDis 28:553-559
65. Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56:66-78
66. Belyaev ND, Nalivaeva NN, Makova NZ, Turner AJ (2009) Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 10:94-100
67. Sen A, Alkon DL, Nelson TJ (2012) Apolipoprotein E3 (ApoE3) but no ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. J Biol Chem 287:15947-15958
68. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid β-peptide deposition in cerebral cortex as consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653
69. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10:333-344
70. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and Apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. doi: 10.1101/cshperspect.a006312
71. Assema DM, Lubberink M, Rizzu P, Swieten JC, Schuit RC, Eriksson J, Scheltens P, Koepp M, Lammertsma AA, Berckel BN (2012) Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res 16:57
72. Erickson MA, Hansen K, Banks WA (2012) Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine. Brain Behav Immun 26:1085-1094
73. Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA (2012) Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation 9:150
74. Assema DM, Goos JD, van der Flier WM, Lubberink M, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN (2012) No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds. J Cereb Blood Flow Metab 32:1468-1471
75. Durk MR, Chan GN, Campos CR, Peart JC, Chow EC, Lee E, Cannon RE, Bendayan R, Miller DS, Sandy PK (2012) 1α,25-Dihydroxyvitamin D(3)-liganded Vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells. J Neurochem. doi: 10.1111/jnc.12041
76. Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Steffen J, Schumacher T, Brüning T, Plath AS, Alfen F, Schmidt A, Winter F, Rateitschak K, Wree A, Gsponer J, Walker LC, Pahnke J (2011) Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. J Clin Invest 121:3924-3931
77. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M (2010) Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis. Science 330:980-982
78. Sagare AP, Winkler EA, Bell RD, Deane R, Zlokovic BV (2011) From the liver to the blood-brain barrier: an interconnected system regulating brain amyloid-β levels. J Neurosci Res 89:967-968
79. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS (2011) Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. J Neurosci Res 89:808-814
80. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. ProcNatl Acad Sci USA 109:3510-3515
81. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, Thiyagarajan M, Zarcone T, Fritz G, Friedman AE, Miller BL, Zlokovic BV (2012) A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122:1377-1392
82. 2+-calcineurin signaling. J Neurosci 32:8845-8854
83. Poellinger L, Göttlicher M, Gustafsson JA (1992) The dioxin and peroxisome proliferator-activated receptors: nuclear receptors in search of endogenous ligands. Trends Pharmacol Sci 13:241-245
84. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M (2005) Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling. Exp Cell Res 304:91-104
85. Santos MJ, Quintanilla RA, Toro A, Grandy R, Dinamarca MC, Godoy JA, Inestrosa NC (2005) Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem 280:41057-41068
86. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M (2007) Peroxisome proliferator-activated receptor γ up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282:37006-37015
87. Mandrekar-Colucci S, Landreth GE (2011) Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets 15:1085-1097
88. Inestrosa NC, Carvajal FJ, Zolezzi JM, Tapia-Rojas C, Serrano F, Karmelic D, Toledo EM, Toro A, Toro J, Santos MJ (2012) Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease. J Alzheimers Dis. doi: 10.3233/JAD-2012-120397
89. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC (2005) Interaction of nuclear receptors with the Wnt/β-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 26:898-915
90. Hollenberg AN (2012) Metabolic health and nuclear-receptor sensitivity. N Engl J Med 366:1345-1347
91. Neher MD, Weckbach S, Huber-Lang MS, Stahel PF (2012) New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Res. doi: 10.1155/2012/728461
92. Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, Lin TN (2012) Peroxisome proliferator-activated receptor gamma (PPAR-γ) and neurodegenerative disorders. Mol Neurobiol. doi: 10.1007/s12035-012-8259-8
93. Heneka MT, Landreth GE (2007) PPARs in the brain. Biochim Biophys Acta 177:1031-1045
94. Watson GS, Craft S (2003) The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17:27-45
95. Polvani S, Tarocchi M, Galli A (2012) PPARγ and oxidative stress: Con(β) catenating NRF2 and FOXO. PPAR Res. doi: 10.1155/2012/641087
96. Martín A, Pérez-Girón JV, Hernanz R, Palacios R, Briones AM, Fortuño A, Zalba G, Salaices M, Alonso MJ (2012) Peroxisome proliferator-activated receptor-γ activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens 30:315-326
97. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC (2004) Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev 47:275-289
98. LaFerla FM (2012) Preclinical success against Alzheimer's disease with an old drug. N Engl J Med 367:570-572
99. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 12:681-693
100. Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32:10117-10128
101. Biserni A, Giannessi F, Sciarroni AF, Milazzo FM, Maggi A, Ciana P (2008) In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio- 5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886). Mol Pharmacol 73:1434-1443
102. Hoque MT, Robillard KR, Bendayan R (2012) Regulation of breast cancer resistant protein by peroxisome proliferator-activated receptor α in human brain microvessel endothelial cells. Mol Pharmacol 81:598-609
103. Mysiorek C, Culot M, Dehouck L, Derudas B, Bordet R, Cecchelli R, Fenart L, Berezowski V (2009) Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier. Curr Neurovasc Res 6:181-193
104. Yin KJ, Deng Z, Hamblin M, Xiang Y, Huang H, Zhang J, Jiang X, Wang Y, Chen YE (2010) Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci 30:6398-6408
105. Kalinin S, Richardson JC, Feinstein DL (2009) A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res 6:431-437
106. Huang W, Eum SY, András IE, Hennig B, Toborek M (2009) PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junctions proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 23:1596-1606
107. Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, Persidsky Y (2008) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol 180:1854-1865
108. Huang W, András IE, Rha GB, Hennig B, Toborek M (2011) PPARα and PPARγ protect against HIV-induced MMP-9 overexpression via caveolae-associated ERK and Akt signaling. FASEB J 25:3979-3988
109. Araújo CV, Estato V, Tibiriçá E, Bozza PT, Castro-Faria-Neto HC, Silva AR (2012) PPAR gamma activation protects the brain against microvascular dysfunction in sepsis. Microvasc Res 84:218-221
110. Min LJ, Mogi M, Shudou M, Jing F, Tsukuda K, Ohshima K, Iwanami J, Horiuchi M (2012) Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 59:1079-1088
111. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's disease. Nature 382:120-121
112. Abramov AY, Canevari L, Duchen MR (2004) Β-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24:565-575
113. Small SA, Gandy S (2006) Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 60:534-542
114. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19:2040-2041
115. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15:1437-1449
116. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med 14:45-53
117. Karran E, Mercken M, de Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698-712
118. Miranda S, Opazo C, Larrondo LF, Muñoz FJ, Leighton F, Inestrosa NC (2000) The role of oxidative stress in the toxicity induced by amyloid β-peptide in Alzheimer's disease. Prog Neurobiol 62:633-648
119. Hernanz R, Martín A, Pérez-Girón JV, Palacios R, Briones AM, Miguel M, Salaices M, Alonso MJ (2012) Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress. Br J Pharmacol 166:1303-1319
120. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B (2012) Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci USA 109:E1369-1376
121. Patterson AD, Shah YM, Matsubara T, Krausz KW, Gonzales FJ (2012) Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology 56:281-290
122. Jiang Q, Heneka M, Landreth GE (2008) The role of peroxisome proliferator-activated receptor-γ (PPARγ) in Alzheimer's disease. CNS Drugs 22:1-14
123. Inestrosa NC, Toledo EM (2008) The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease. Molec Neurodegener 3:9
124. Almeida M, Han L, Martín-Millan M, O'Brien CA, Manolagas SC (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 282:27298-27305
125. Manolopoulos KN, Klotz L-O, Korsten P, Bornstein SR, Barthel A (2010) Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry 15:1046-1052
126. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127:397-408
127. Waresky P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A (2009) PGC-1α and PGC-1β regulates mitochondrial density in neurons. J Biol Chem 284:21379-21385
128. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1α by mutant Huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59-69
129. Martin E, Betuing S, Pagès C, Cambon K, Auregan G, Deglon N, Roze E, Caboche J (2011) Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatine remodeling at the PGC-1-alpha promoter. Hum Mol Genet 20:2422-2434
130. Toledo EM, Inestrosa NC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15:272-285
131. Hondares E, Rosell M, Díaz-Delfin J, Olmos Y, Monsalve M, Iglesias R, Villarroya F, Giralt M (2011) Peroxisome proliferator-activated receptor α (PPARα) induces PPARγcoactivator 1α (PGC-1α) gene expression and contributes to thermogenic activation of brown fat. J Biol Chem 286:43112-43122
132. Lowenthal J, Hull SC, Pearson SD (2012) The ethics of early evidence - preparing for a possible breakthrough in Alzheimer's disease. N Engl J Med 367:488-490
133. Mehdipour AR, Hamidi M (2009) Brain drug targeting: a computational approach for overcoming blood-brain barrier. Drug Discov Today 14:1030-1036
134. Raffa V, Gherardini L, Vittorio O, Bardi G, Ziaei A, Pizzorusso T, Riggio C, Nitodas S, Karachalios T, Al-Jamal KT, Kostarelos K, Costa M, Cuschieri A (2011) Carbon nanotube-mediated wireless cell permeabilization: drug and gene uptake. Nanomedicine (Lond) 6:1709-1718